✦ LIBER ✦

Alemtuzumab versus interferon beta-1a: implications for pathology and trial design

✍ Scribed by Henry F McFarland

Book ID: 114409103
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 259 KB
Volume: 8
Category: Article
ISSN: 1474-4465
DOI: 10.1016/s1474-4422(08)70280-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab versus interferon beta 1a as

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

✍ Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edwar 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 334 KB

Alemtuzumab versus interferon beta-1a in

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

✍ Alasdair J Coles; Edward Fox; Anton Vladic; Suzanne K Gazda; Vesna Brinar; Krzys 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 306 KB

Interferon beta-1a as adjunctive treatme

Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial

✍ Alexander J. Radziwill; Stephan A. Botez; Jan Novy; Thierry Kuntzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

PND6 GLATIRAMER ACETATE VERSUS INTERFERO

PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

✍ J Castelli-Haley; M Oleen-Burkey; MJ Lage; K Johnson 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Extended observations on MS patients tre

Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics

✍ Lawrence Jacobs; Richard Rudick; Jack Simon 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Extended observations on MS patients tre

Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics

✍ Lawrence Jacobs; Richard Rudick; Jack Simon 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Extended observations of the pivotal phase III clinical trial of interferon-beta1a (IFNbeta1a; Avonex, Biogen) in relapsing MS patients revealed that: (1) active treatment significantly slowed the accumulation of physical disability over time, reduced clinical exacerbations and MRI brain lesions; (2